Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | MMP2 | P08253 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | FNTA | P49354 | 1/20 | 0.78 |
| ▸ | FNTB | P49356 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 12/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.77 |
| ▸ | RECQL | P46063 | 8/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.77 |
| ▸ | USP2 | O75604 | 5/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | HBB | P68871 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 10/20 | 0.67 |
| ▸ | THRB | P10828 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | CASP1 | P29466 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aclarubicin SCHEMBL2804048 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL31277372 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL1649619 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL29390785 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL10079204 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL17035568 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL6255351 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL10201119 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL31238004 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL17167135 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034851-B2 | Metal-salen complex compound, local anesthetic and antineoplastic drug | IHI CORPORATION (JP) | 2018-07-31 | — | — | US | disclosed |
| US-9505732-B2 | Auto magnetic metal salen complex compound | IHI CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-20160263074-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | ISHIKAWA YOSHIHIRO (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20160263074-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | ISHIKAWA YOSHIHIRO (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20140206635-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | IHI CORPORATION (JP) | 2014-07-24 | — | — | US | disclosed |
| US-20140206635-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | IHI CORPORATION (JP) | 2014-07-24 | — | — | US | disclosed |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | IHI CORPORATION (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | IHI CORPORATION (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | YOSHIHIRO ISHIKAWA (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | SDHB, SDHA, SLC40A1 | PTGS1 2657/4885MMP2 3160/4885HTR2B 3154/4885 |
| US-20140206635-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | NCLN, KCNN2, NCSTN | PTGS1 2488/4885MMP2 1230/4885HTR2B 4376/4885 |
| US-10034851-B2 | Metal-salen complex compound, local anesthetic and antineoplastic drug | NCLN, KCNN2, NCSTN | PTGS1 2488/4885MMP2 1230/4885HTR2B 4376/4885 |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | SSBP1, KCNN1, IMMT | PTGS1 2016/4885MMP2 2736/4885HTR2B 3237/4885 |
| US-20160263074-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | NCLN, KCNN2, NCSTN | PTGS1 2488/4885MMP2 1230/4885HTR2B 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.